Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

The "Poverty, Prosperity, and Planet. Pathways Out of the Polycrisis" report evaluates progress towards these goals. It offers the first global assessment of poverty and shared prosperity ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. President Donald Trump’s first month in office has been dizzying for U.S ...

Not all pathways are offered by all programmes ... Open Modules are modules that are related to or complement your discipline. Each programme offers a range of Open Modules, providing opportunities ...

Synthesis planning often begins with the design of a reaction pathway from a starting precursor to a target molecule. Recently, asymmetric synthesis of a therapeutic drug (+)-Xyloketal B was achieved ...

Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852, United States ...

A recent Brazilian study published in Nature Cardiovascular Research has highlighted promising pathways for preventing and treating atrial fibrillation, a condition that significantly raises the ...